Abstract
LG-65. CLINICOPATHOLOGICAL FEATURES AND OUTCOME IN ADOLESCENTS/YOUNG ADULTS (AYA) WITH LOW GRADE GLIOMA (LGG) COMPARED WITH CHILDREN: A REPORT FROM THE CHILDREN’S ONCOLOGY GROUP Ashley Margol1,3, Caihong Xia4, Richard Sposto2,3, David Freyer1,3, and Girish Dhall1,3; Department of Pediatrics, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA; Department of Preventive Medicine, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA; Children’s Hospital Los Angeles, Los Angeles CA, USA; Children’s Oncology Group, Monrovia, CA, USA LGGs represent a heterogeneous group of tumors that occur across age groups and are the most common central nervous system tumors in children. AYA represent a unique subset of patients whose disease presentation, pathology and outcome often differ compared with children and adults. While differences in pediatric and adult LGGs have been established, potential differences in the presentation, pathology, and outcome of children versus AYA with LGGs have not been interrogated. We hypothesized that there are age-related differences in clinicopathological features and outcome in patients with LGGs. We performed a retrospective secondary analysis of a legacy CCG dataset (CCG9891/POG9130) to determine if differences exist between childrenand AYAwith LGGs managed primarily with surgery.Children and AYA were defined as ages 0 to 14 and 15 to 21 years, respectively. The following parameters for children (n 1⁄4 468) were compared to those of AYA (n 1⁄4 50): sex, race/ethnicity, pathological features, tumor location, incidence of seizures at presentation, level of consciousness at presentation, extent of resection, incidence of surgical complications, event-free survival (EFS), pattern of relapse and overall survival (OS). When comparing children and AYA, there were no statistically significant age-related differences in any of these clinicopathological features or EFS, OS, and pattern of relapse. In conclusion, LGGs occurring in AYA have similar clinicopathological features to those occurring in children. Our findings suggest that treatment paradigms and clinical trials for childhood LGG are appropriate for use among AYA. Neuro-Oncology 18:iii78–iii96, 2016. doi:10.1093/neuonc/now075.65 #The Author(s) 2016. Published by Oxford University Press on behalf of the Society for Neuro-Oncology. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.